Vectura was founded in 1997. In June 2016, the company merged with Skyepharma, a former portfolio company of HBM Healthcare. Complementary technologies have created a world leader in inhalation therapies with a market value of over GBP 1 billion. The merger enabled both companies to significantly expand their revenue base.